Furaprofen

Research use only, not for human use.

Furaprofen is an orally available, selective and potent HCV inhibitor with anti-inflammatory activity, inhibits carrageenan-induced paw edema in rats and inhibits cotton pellet-induced granulomas in rats at higher doses.

Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50, ~30 nM) than against the genotype 2a replicon (EC50, ~1,000 nM).

Furaprofen (R803) is potent and highly specific for HCV replication. The antiviral activity of Furaprofen has been determined by a reporter replicon assay with multiple repeats to be 29.88±8.05 nM, an ~3-fold improvement over the activity of the parent compound, R706. The potency of Furaprofen against the replicon is also confirmed by both Western blotting and TaqMan RT-PCR to be about 37 nM and 54.67±4.11 nM, respectively. To assess the general effect of Furaprofen on cell proliferation, a panel of primary cells and transformed human cell lines are treated with increasing doses of Furaprofen for 48 h, and the effect on cell proliferation is measured by an MTS-based cell viability assay. The the concentration that caused a 50% reduction in cell numbers in the absence of virus infection (CC50)of Furaprofen is found to range from 2 μM to ≥10 μM, depending on the cell type and proliferation status.

——

——

Others

Other Targets

HCV Protease

——

——

67700-30-5

266.29

C17H14O3

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (938.83 mM; Ultrasonic )

CC(C(O)=O)c1cccc2c(coc12)-c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years